Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.

Sci Signal. 2018 Oct 9;11(551). pii: eaat9773. doi: 10.1126/scisignal.aat9773.

PMID:
30301790
2.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31.

3.

Effect of dietary GLA+/-tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts.

Kenny FS, Gee JM, Nicholson RI, Ellis IO, Morris TM, Watson SA, Bryce RP, Robertson JF.

Int J Cancer. 2001 May 1;92(3):342-7.

4.

Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells.

Jiang WG, Redfern A, Bryce RP, Mansel RE.

Prostaglandins Leukot Essent Fatty Acids. 2000 Feb;62(2):119-27.

PMID:
10780877
5.

Gamma linolenic acid with tamoxifen as primary therapy in breast cancer.

Kenny FS, Pinder SE, Ellis IO, Gee JM, Nicholson RI, Bryce RP, Robertson JF.

Int J Cancer. 2000 Mar 1;85(5):643-8.

7.

Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications.

Jiang WG, Bryce RP, Horrobin DF.

Crit Rev Oncol Hematol. 1998 Apr;27(3):179-209. Review. No abstract available.

PMID:
9649932
8.

Regulation of tight junction permeability and occludin expression by polyunsaturated fatty acids.

Jiang WG, Bryce RP, Horrobin DF, Mansel RE.

Biochem Biophys Res Commun. 1998 Mar 17;244(2):414-20.

PMID:
9514943
9.

The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells.

Jiang WG, Hiscox S, Bryce RP, Horrobin DF, Mansel RE.

Br J Cancer. 1998 Mar;77(5):731-8.

10.

Regulation of desmosomal cell adhesion in human tumour cells by polyunsaturated fatty acids.

Jiang WG, Singhrao SK, Hiscox S, Hallett MB, Bryce RP, Horrobin DF, Puntis MC, Mansel RE.

Clin Exp Metastasis. 1997 Nov;15(6):593-602.

PMID:
9344043
11.

Gamma linolenic acid regulates expression of maspin and the motility of cancer cells.

Jiang WG, Hiscox S, Horrobin DF, Bryce RP, Mansel RE.

Biochem Biophys Res Commun. 1997 Aug 28;237(3):639-44.

PMID:
9299418
12.

Gamma linolenic acid regulates gap junction communication in endothelial cells and their interaction with tumour cells.

Jiang WG, Bryce RP, Mansel RE.

Prostaglandins Leukot Essent Fatty Acids. 1997 Apr;56(4):307-16.

PMID:
9150377

Supplemental Content

Loading ...
Support Center